[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354255-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354255-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immunotherapy-based-neoadjuvant-treatment-of-gastric-cancer-with-elevated-serum-afp-a-case-report","Immunotherapy-based neoadjuvant treatment of gastric cancer with elevated serum AFP: a case report","","Alpha-fetoprotein-producing gastric cancer (AFPGC) is a rare, highly malignant subtype with limited standardized treatment options and generally poor outcomes. Six Asian patients with locally advanced, non-metastatic AFPGC received immunotherapy combined with neoadjuvant chemotherapy. Five patients achieved pathologic complete response and one achieved pathologic partial remission, with no recurrence during postoperative follow-up. The regimen was well tolerated and supported quality of life. Immune checkpoint inhibitors plus chemotherapy may offer benefit for AFPGC, warranting further mechanistic study.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immunotherapy-based-neoadjuvant-treatment-of-gastric-cancer-with-elevated-serum-afp-a-case-report/354255/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immunotherapy-based-neoadjuvant-treatment-of-gastric-cancer-with-elevated-serum-afp-a-case-report/354255.png","ImageObject",300,407,{"name":42,"@type":43},"eBook King","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main clinical concern with alpha-fetoprotein-producing gastric cancer (AFPGC) addressed in this report?","Question",{"text":63,"@type":64},"AFPGC is rare and highly aggressive, with poor prognosis and limited established standardized treatment options.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment approach was evaluated for the six AFPGC patients?",{"text":68,"@type":64},"The report describes a retrospective use of neoadjuvant chemotherapy combined with immunotherapy, including immune checkpoint inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes and follow-up results were reported after treatment?",{"text":72,"@type":64},"Five patients achieved pathologic complete response and one achieved pathologic partial remission, and no recurrence was observed during postoperative follow-up.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354255,1790193572,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Liu et al. Journal of Medical Case Reports (2026) 20:299  \n[https://doi.org/10.1186/s13256-026-06055-2](https://doi.org/10.1186/s13256-026-06055-2)  \nJournal of Medical Case Reports  \n CASE REPORT Open Access  \nImmunotherapy-based neoadjuvant  \ntreatment of gastric cancer with elevated serum AFP: a case report  \nYuanlin Liu1, Dong Yang1, Xiangyu Meng1, Jun Zhang1, Chao Wang1, Meng Zhang1, Junqiao Yao1, Qian Dong2, Yue Dong3, Yanmei Zhu4, Deyu Sun5, Jingdong Zhang2 and Tao Zhang1*  \nAbstract  \nBackground Alpha-fetoprotein-producing gastric cancer (AFPGC) is a rare type of gastric cancer with a high degree of malignancy and a poor prognosis. The standardized treatment process for this type of gastric cancer has not yet been defined, and the available treatment options are limited. However, with the development of molecular biology and immunology, more therapeutic options are available for gastric cancer patients. Immunotherapy has made substantial progress in the treatment of many solid tumors, but there are rare reports on the therapeutic efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with AFPGC.  \nCase presentation We conducted a retrospective analysis of six Asian patients with AFPGC, among them were four males and two females, aged 61, 66, 63, 72, 70, and 72 years, respectively, all of whom were Asian. Five of the patients achieved pathologic complete response (pCR) and one patient pathologic partial remission by combining chemotherapy and immunotherapy, and no recurrence was observed during postoperative follow-up. Moreover, the treatment was well tolerated and the quality of life of the patients was assured during the treatment period.  \nConclusions We report six cases of locally advanced, non-metastatic gastric cancer with elevated AFP, all of which demonstrated a favorable response and were well tolerated by the patients after the use of immune checkpoint inhibitors and neoadjuvant chemotherapy. This study suggests that programmed death receptor 1(PD-1) checkpoint inhibitors plus chemotherapy can benefit patients with AFPGC and provide a reference for the treatment of patients with AFPGC, and its mechanism of action deserves further study.  \nKeywords AFPGC, Immunotherapy, Case report  \n*Correspondence: Tao Zhang [Zhangtao1521@126.com](Zhangtao1521@126.com)  \n1 Department of Gastrosurgery, Liaoning Cancer Hospital &Institute, Shenyang 10042, China  \n2 Department of Gastroenterology, Liaoning Cancer Hospital &Institute, Shenyang 10042, China  \n3 Department of Radiology, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang 110042, Liaoning, China  \n4 Department of Pathology, Affiliated Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University), Shenyang, China  \n5 Department of Radiation Oncology Gastrointestinal and Urinary and Musculoskeletal Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not pe","cbCaiiZ4K7lCO6aF","https://ap.wps.com/l/cbCaiiZ4K7lCO6aF","pdf",1401557,11,"English","# Abstract\n# Case presentation\n# Conclusions\n# Keywords\n# Introduction","[{\"question\":\"What is the main clinical concern with alpha-fetoprotein-producing gastric cancer (AFPGC) addressed in this report?\",\"answer\":\"AFPGC is rare and highly aggressive, with poor prognosis and limited established standardized treatment options.\"},{\"question\":\"What treatment approach was evaluated for the six AFPGC patients?\",\"answer\":\"The report describes a retrospective use of neoadjuvant chemotherapy combined with immunotherapy, including immune checkpoint inhibitors.\"},{\"question\":\"What outcomes and follow-up results were reported after treatment?\",\"answer\":\"Five patients achieved pathologic complete response and one achieved pathologic partial remission, and no recurrence was observed during postoperative follow-up.\"}]","Immunotherapy-based neoadjuvant treatment of gastric cancer with elevated serum AFP: a case report | PDF",1790109737,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b730616b5353fc61bad6042a38893aa7.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6085f8f968e230cac8fea8d12934efb.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce1582c141a45dd5e2534c658d699826.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a8f9952980804e2ffe50e521b0e6416.webp",980,1301]